Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Antimicrob Agents Chemother ; 68(5): e0028024, 2024 May 02.
Article in English | MEDLINE | ID: mdl-38587391

ABSTRACT

Testing Plasmodium vivax antimicrobial sensitivity is limited to ex vivo schizont maturation assays, which preclude determining the IC50s of delayed action antimalarials such as doxycycline. Using Plasmodium cynomolgi as a model for P. vivax, we determined the physiologically significant delayed death effect induced by doxycycline [IC50(96 h), 1,401 ± 607 nM]. As expected, IC50(96 h) to chloroquine (20.4 nM), piperaquine (12.6 µM), and tafenoquine (1,424 nM) were not affected by extended exposure.


Subject(s)
Aminoquinolines , Antimalarials , Doxycycline , Piperazines , Plasmodium cynomolgi , Plasmodium vivax , Doxycycline/pharmacology , Antimalarials/pharmacology , Aminoquinolines/pharmacology , Plasmodium vivax/drug effects , Plasmodium cynomolgi/drug effects , Chloroquine/pharmacology , Animals , Malaria, Vivax/drug therapy , Malaria, Vivax/parasitology , Quinolines/pharmacology , Inhibitory Concentration 50 , Humans , Parasitic Sensitivity Tests
2.
Int J Antimicrob Agents ; 63(5): 107112, 2024 May.
Article in English | MEDLINE | ID: mdl-38367843

ABSTRACT

The control and elimination of malaria caused by Plasmodium vivax is hampered by the threat of relapsed infection resulting from the activation of dormant hepatic hypnozoites. Currently, only the 8-aminoquinolines, primaquine and tafenoquine, have been approved for the elimination of hypnozoites, although their use is hampered by potential toxicity. Therefore, an alternative radical curative drug that safely eliminates hypnozoites is a pressing need. This study assessed the potential hypnozoiticidal activity of the antibiotic azithromycin, which is thought to exert antimalarial activity by inhibiting prokaryote-like ribosomal translation within the apicoplast, an indispensable organelle. The results show that azithromycin inhibited apicoplast development during liver-stage schizogony in P. vivax and Plasmodium cynomolgi, leading to impaired parasite maturation. More importantly, this study found that azithromycin is likely to impair the hypnozoite's apicoplast, resulting in the loss of this organelle. Subsequently, using a recently developed long-term hepatocyte culture system, this study found that this loss likely induces a delay in the hypnozoite activation rate, and that those parasites that do proceed to schizogony display liver-stage arrest prior to differentiating into hepatic merozoites, thus potentially preventing relapse. Overall, this work provides evidence for the potential use of azithromycin for the radical cure of relapsing malaria, and identifies apicoplast functions as potential drug targets in quiescent hypnozoites.


Subject(s)
Antimalarials , Apicoplasts , Azithromycin , Liver , Plasmodium cynomolgi , Plasmodium vivax , Azithromycin/pharmacology , Plasmodium vivax/drug effects , Plasmodium cynomolgi/drug effects , Antimalarials/pharmacology , Liver/parasitology , Liver/drug effects , Apicoplasts/drug effects , Animals , Hepatocytes/parasitology , Hepatocytes/drug effects , Humans , Organelle Biogenesis , Malaria, Vivax/parasitology , Malaria, Vivax/drug therapy , Mice , Malaria/parasitology , Malaria/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL